临床肿瘤学杂志
• 综述与讲座 • 上一篇 下一篇
杨明威,杨林
收稿日期:
修回日期:
出版日期:
发布日期:
通讯作者:
YANG Mingwei, YANG Lin
Received:
Revised:
Online:
Published:
Contact:
摘要: 随着抗血管生成治疗恶性肿瘤理论的提出,重组人血管内皮抑素(恩度)作为一种新型的抗肿瘤药物,与传统的放疗联合具有协同作用,在基础及临床研究中均证实了恩度的放疗增敏作用。可能机制包括改善肿瘤内乏氧情况,作用于血管内皮细胞,调整细胞周期和调节促血管生成因子水平等。将恩度与放疗联合有望成为一种新的治疗策略应用于临床,提高恶性肿瘤的治疗效果。
Abstract: With the theory of anti-angiogenesis therapy for malignant tumors, recombinant human endostatin(Endostar)as a promising novel medicine to treat malignant tumors,represents synergistic antitumor effects in combination with conventional radiotherapy. Its radiosensitization effect has been demonstrated by a variety of laboratory and clinical experiments,and the underlying mechanisms may include normalizing tumor vasculature,alleviating inner hypoxia,inhibiting endothelial cell proliferation and migration,inducing endothelial cell apoptosis,cell cycle changes,and angiogenic factors regulation. Endostar in combination with radiotherapy may become a new and effective treatment strategy of anti-cancer.
杨明威,杨林. 重组人血管内皮抑制素与放射治疗敏感性的相关性研究进展[J]. 临床肿瘤学杂志, 2014, 19(1): 82-.
YANG Mingwei, YANG Lin. Advance in the radiosensitization effect of recombinant human endostatin[J]. Chinese Clinical Oncology, 2014, 19(1): 82-.
0 / / 推荐
导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks
链接本文: http://manu65.magtech.com.cn/Jwk3_lczlxzz/CN/
http://manu65.magtech.com.cn/Jwk3_lczlxzz/CN/Y2014/V19/I1/82
Cited